



Washington — The lack of a sufficient physician appeals process and other issues have physicians concerned about a new regulation that will allow the release of Medicare claims data for developing doctor quality scores starting in 2012.
On Dec. 5, the Centers for Medicare & Medicaid Services finalized a regulation granting access to physician billing data to qualified organizations, including consumer groups and employers. Doctors’ claims from 2009, 2010 and the first two quarters of 2011 will be available for analysis starting next year, according to the final rule
This is a giant step forward in making our health care system more transparent and promoting increased competition, accountability, quality and lower costs,” said acting CMS Administrator Marilyn Tavenner. “This provision of the health care law will ensure consumers have the access they deserve to information that will help them receive the highest quality care at the best value for their dollar.”
To qualify, groups must show that they have experience evaluating performance measures, analyzing claims data and safeguarding information. Entities also are required to have access to claims data from other health payers, either private insurers or public payers such as Medicaid, to combine with the Medicare data.
The Medicare agency issued a proposed rule in June on the claims data release. The American Medical Association and 81 other physician organizations wrote a letter in August encouraging CMS to take steps ensuring that the data in performance reports are reliable. If done correctly, public reporting could help improve quality at the point of care, the organizations said.
But the final rule failed to create the mechanisms and safeguards needed to ensure that published information on doctors is correct, said AMA President Peter W. Carmel, MD. In some areas, restrictions on the data were relaxed. For instance, changes from the proposed rule would allow claims data to be distributed even if the accuracy of the information is in dispute and subject to an appeal. Dr. Carmel said this “is misleading to patients and does a disservice to physicians.”
“The AMA supports the use of accurate physician data when it improves quality of care for patients, but we are concerned that CMS’ easing of some requirements for receiving Medicare data could result in the distribution of physician performance reports that are inaccurate and not meaningful for patients or physicians,” he said.
Patient advocacy groups and employers have supported the release of physician billing data. Health coverage has become less affordable, and runaway health spending is adversely affecting other sectors of the economy, the Coalition for Affordable Health Coverage wrote in an August letter in support of data sharing. Improving public access to performance measures “will help facilitate incentives to provide higher-quality, lower-cost care,” the coalition stated.
Transparency is critical to making informed choices about doctors and medical services, the U.S. Chamber of Commerce said in its letter to CMS. “As purchasers of health care coverage and services, employers and individuals are eager to have access to more data on provider performance and quality to permit more informed health care decision-making.”
.
Allergic contact dermatitis (ACD) is a delayed type of induced
sensitivity (allergy) resulting from cutaneous contact with a specific allergen to which the patient has developed a specific sensitivity. This allergic reaction causes inflammation of the skin manifested by varying degrees of erythema, edema, and vesiculation.
The term contact dermatitis sometimes is used incorrectly as a synonym for allergic contact dermatitis. Contact dermatitis is inflammation of the skin induced by chemicals that directly damage the skin (see Irritant Contact Dermatitis) and by specific sensitivity in the case of allergic contact dermatitis.
Jadassohn first described allergic contact dermatitis in 1895. He developed the patch test to identify the chemicals to which the patient was allergic. Sulzberger popularized patch testing in the United States in the 1930s. The Finn chamber method for patch testing was designed in the 1970s; these chambers consist of small metal cups, typically attached to strips of tape, filled with allergens dispersed in either petrolatum or water. The thin-layer rapid use epicutaneous (TRUE) test for patch testing became available in the United States in the 1990s.
The importance of specific substances as causes of allergic contact dermatitis varies with the prevalence of that substance in the environment. Mercury compounds once were significant causes of allergic contact dermatitis but rarely are used as topical medications and, currently, are uncommon as a cause of allergic contact dermatitis. Ethylenediamine, which was present in the original Mycolog cream, declined as a primary cause of allergic contact dermatitis once Mycolog cream was reformulated to no longer contain this allergen.
A detailed history, both before and after patch testing, is crucial in evaluating individuals with allergic contact dermatitis. Before patch testing, the history identifies potential causes of allergic contact dermatitis and the materials to which individuals are exposed that should be included in patch testing. After patch testing, the history determines the clinical significance of the findings. (See Clinical.)